• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

Advertisement

Organisation › Details

Probiodrug AG

Probiodrug is a biopharmaceutical company dedicated to the discovery and development of small molecule drugs against novel molecular targets for the treatment of neuronal- and inflammatory diseases. The Company has a dominant position in the area of glutaminyl cyclase inhibition. Glutaminyl cyclase, a novel enzyme target discovered and patented by Probiodrug, has a crucial role in the pathogenesis of Alzheimer's disease (AD) as well as various peripheral inflammatory diseases. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM, Life Sciences Partners, Biogen Idec Ventures, CFH Group and private investors. Probiodrug's core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. The Company has pioneered the field of dipeptidyl peptidase 4 (DP4)-inhibition for the treatment of type 2 diabetes. Compounds and technology patents of its DP4 program in diabetes were licensed to various pharmaceutical companies. In 2004, all metabolic assets were sold to (OSI) Pharmaceuticals Ltd. The first drug based on Probiodrug`s technologies reached the market in late 2006. Proceeds of the various transactions have been reinvested to fund the novel approach for the treatment of AD and inflammatory diseases. The Company was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund. Probiodrug has so far raised EUR 71 mio for its QC program. *

 

	Start	1997-06-01 established_pre
	Group	Probiodrug (Group)
	Predecessor	Probiodrug Gesellschaft für Arzneimittelforschung mbH
	Region	Halle (Saale)
	Country	Germany
	Street	22 Weinbergweg
	City	06120 Halle (Saale)
	Tel	+49-345-55599-00
	Fax	+49-345-55599-01
		Address record changed: 2012-01-09
Basic data	Employees	n. a.
		* Document for »About Section«: Probiodrug AG. (1/4/12). "Press Release: Probiodrug Raises Additional €15 Million to Advance Its Clinical Program". Halle (Saale).
		Record changed: 2012-01-12

To subscribe to our free, monthly [MSC] Newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

NEW: Visit our brand new forthcoming web portals Life-Sciences-Germany.com and Life-Sciences-Europe.com

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2012. Made in Germany.